Sickle Cell Retinopathy Treatment Market: Introduction

In sickle cell retinopathy disease, vitreous hemorrhage resulting from proliferative sickle cell retinopathy is the primary cause of reduced acuity. The sickle cell retinopathy treatment strategy is based on closing the sea fan (Gorgonia flabelum). Patients in stages I and II are barred from treatment because treatment associated with ischemic retina is ineffective in limiting the formation of Sea fan (SF), and the majority of patients do not develop Sea fan or its complications.

The treatment is still considered controversial because many Sea fan degenerate spontaneously, especially in older SS genotype patients, in whom the incidence of blindness is very small. Therefore, the recommended approach is to treat Sea fan in all SC patients and SS genotype patients below 40 years of age with sectorial technique.

Patients with visual acuity impairment and recent vitreous hemorrhage cases are usually tracked for at least 7-8 months to allow extemporaneous clearing. cryotherapy or photocoagulation can be performed when the visibility permits it. The current advancement in Sickle cell retinopathy treatment symptomatically in rapidly recovering the vision disturbance in the eye is anticipated to increase the adoption of Sickle cell retinopathy treatment in treatment providers.

The significant factor driving the growth of sickle cell retinopathy treatment market is the increasing number of new molecules in the pipeline and also the symptomatic treatment molecules which the government regulatory bodies are approving. Sickle cell retinopathy treatment has given a new area of expansion for market players already in the sickle cell retinopathy treatment market and for those who are trying to establish a new area in this market. Therapeutic devices has been granted in U.S. for its significant treatment regimen, for the treatment of sickle cell retinopathy.

The device has been granted a patent for its treatment of sickle cell disease. Moreover, researchers have moved ahead of treating sickle cell disease by antibiotics to the genome level.

Researchers from Stanford School of Medicine successfully corrected the genes carrying the gene for sickle cell disease and transplanted those with healthy cells. By using the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) technique, researchers replaced the sickle cell disease cell genes with the one which did not carry that gene.

On the contrary, the high cost related to the Sickle cell retinopathy treatment and rigid reimbursement policy in treatment is anticipated to restrain the growth of Sickle cell retinopathy treatment market.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Market Segmentation

Treatment Type	Long-term blood transfusions Photocoagulation Others (HBOT, stem cells, and gene therapy)
Disease Type	Proliferative Retinopathy Non-Proliferative Retinopathy
Distribution Channel	Institutional sales Hospitals Clinics Retail sales Hospitals pharmacy Retail Pharmacy Drug Stores
Region	North America Latin America Europe East Asia South Asia Oceana Middle East & Africa